140 related articles for article (PubMed ID: 36430230)
41. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
42. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression.
Witzens-Harig M; Giaisi M; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2016 Jan; 138(2):507-14. PubMed ID: 26260669
[TBL] [Abstract][Full Text] [Related]
43. In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells.
Montoya JJ; Turnidge MA; Wai DH; Patel AR; Lee DW; Gokhale V; Hurley LH; Arceci RJ; Wetmore C; Azorsa DO
BMC Cancer; 2019 Dec; 19(1):1251. PubMed ID: 31881855
[TBL] [Abstract][Full Text] [Related]
44. BCL-x
Faqar-Uz-Zaman SF; Heinicke U; Meister MT; Vogler M; Fulda S
Cancer Lett; 2018 Jan; 412():131-142. PubMed ID: 28947136
[TBL] [Abstract][Full Text] [Related]
45. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
46. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis.
Lagares D; Santos A; Grasberger PE; Liu F; Probst CK; Rahimi RA; Sakai N; Kuehl T; Ryan J; Bhola P; Montero J; Kapoor M; Baron M; Varelas X; Tschumperlin DJ; Letai A; Tager AM
Sci Transl Med; 2017 Dec; 9(420):. PubMed ID: 29237758
[TBL] [Abstract][Full Text] [Related]
47. Computational modeling of DLBCL predicts response to BH3-mimetics.
Cloete I; Smith VM; Jackson RA; Pepper A; Pepper C; Vogler M; Dyer MJS; Mitchell S
NPJ Syst Biol Appl; 2023 Jun; 9(1):23. PubMed ID: 37280330
[TBL] [Abstract][Full Text] [Related]
48. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.
Pécot J; Maillet L; Le Pen J; Vuillier C; Trécesson SC; Fétiveau A; Sarosiek KA; Bock FJ; Braun F; Letai A; Tait SWG; Gautier F; Juin PP
Cell Rep; 2016 Dec; 17(12):3347-3358. PubMed ID: 28009301
[TBL] [Abstract][Full Text] [Related]
49. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
50. BH3 mimetic-elicited Ca
Ferdek PE; Jakubowska MA; Nicolaou P; Gerasimenko JV; Gerasimenko OV; Petersen OH
Cell Death Dis; 2017 Mar; 8(3):e2640. PubMed ID: 28252652
[TBL] [Abstract][Full Text] [Related]
51. [BH3 mimetics as a strategy to complement anticancer therapies].
Hartman MŁ; Czyż M
Postepy Hig Med Dosw (Online); 2012 Feb; 66():67-77. PubMed ID: 22371408
[TBL] [Abstract][Full Text] [Related]
52. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.
Dai H; Ding H; Meng XW; Peterson KL; Schneider PA; Karp JE; Kaufmann SH
Genes Dev; 2015 Oct; 29(20):2140-52. PubMed ID: 26494789
[TBL] [Abstract][Full Text] [Related]
53. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells.
Johnson-Farley N; Veliz J; Bhagavathi S; Bertino JR
Leuk Lymphoma; 2015 Jul; 56(7):2146-52. PubMed ID: 25373508
[TBL] [Abstract][Full Text] [Related]
54. Optimization and validation of mitochondria-based functional assay as a useful tool to identify BH3-like molecules selectively targeting anti-apoptotic Bcl-2 proteins.
Long J; Liu L; Nikolovska-Coleska Z; Shangary S; Yi H; Wang S; Wang S
BMC Biotechnol; 2013 May; 13():45. PubMed ID: 23705845
[TBL] [Abstract][Full Text] [Related]
55. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
[TBL] [Abstract][Full Text] [Related]
56. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
Márk Á; Hajdu M; Váradi Z; Sticz TB; Nagy N; Csomor J; Berczi L; Varga V; Csóka M; Kopper L; Sebestyén A
BMC Cancer; 2013 May; 13():250. PubMed ID: 23693095
[TBL] [Abstract][Full Text] [Related]
57. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
58. Sensitivity of Cutaneous T-Cell Lymphoma Cells to the Mcl-1 Inhibitor S63845 Correlates with the Lack of Bcl-w Expression.
Sumarni U; Zhu J; Sinnberg T; Eberle J
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293331
[TBL] [Abstract][Full Text] [Related]
59. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.
Koss B; Ryan J; Budhraja A; Szarama K; Yang X; Bathina M; Cardone MH; Nikolovska-Coleska Z; Letai A; Opferman JT
Oncotarget; 2016 Mar; 7(10):11500-11. PubMed ID: 26862853
[TBL] [Abstract][Full Text] [Related]
60. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
